Altimmune Inc (ALT) concluded trading on Wednesday at a closing price of $9.85, with 10.94 million shares of worth about $107.75 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 34.93% during that period and on December 04, 2024 the price saw a gain of about 12.06%. Currently the company’s common shares owned by public are about 71.12M shares, out of which, 70.53M shares are available for trading.
Stock saw a price change of 16.84% in past 5 days and over the past one month there was a price change of 45.07%. Year-to-date (YTD), ALT shares are showing a performance of -12.44% which increased to 112.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.06 but also hit the highest price of $14.84 during that period. The average intraday trading volume for Altimmune Inc shares is 2.79 million. The stock is currently trading 18.38% above its 20-day simple moving average (SMA20), while that difference is up 34.99% for SMA50 and it goes to 30.20% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Altimmune Inc (NASDAQ: ALT) currently have 71.12M outstanding shares and institutions hold larger chunk of about 56.20% of that.
The stock has a current market capitalization of $700.58M and its 3Y-monthly beta is at 0.15. It has posted earnings per share of -$1.55 in the same period. It has Quick Ratio of 16.87 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALT, volatility over the week remained 9.15% while standing at 11.20% over the month.
Stock’s fiscal year EPS is expected to rise by 17.37% while it is estimated to increase by 9.34% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on November 12, 2024 offering a Buy rating for the stock and assigned a target price of $26 to it. On January 24, 2024, Goldman Initiated their recommendations, while on March 22, 2023, Goldman Downgrade their ratings for the stock with a price target of $6. Stock get a Buy rating from Goldman on December 01, 2022.
